from the hormones-growing dept.
McLuhanesque writes "The Globe and Mail reports that a Calgary biotech firm has developed a process to turn genetically modified safflower oil into human insulin in commercial quantities. The process reduces capital costs by 70% and product cost by 40%. 'SemBioSys says it can make more than one kilogram of human insulin per acre of safflower production. That amount could treat 2,500 diabetic patients for one year and, in turn, meet the world's total projected insulin demand in 2010 with less than 16,000 acres of safflower production.'"
Economists state their GNP growth projections to the nearest tenth of a
percentage point to prove they have a sense of humor.
-- Edgar R. Fiedler